Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 ...

Immatics’ cell therapy has been linked to a 56% objective response rate (ORR) among 32 heavily pretreated patients with ...

Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes Melanoma brain metastases are a substantial contributor to mortality in patients with metastatic melanoma, and treatment ...